Industry

A 9.7-month median progression-free survival (mPFS) was reached for the 50mg twice-daily (BID) casdatifan monotherapy cohort of the Phase 1/1b ARC-20 study; mPFS was not yet reached for other cohorts Across all three monotherapy cohorts presented, casdatifan demonstrated improvements in the rate of primary progression, overall response rate (ORR) and progression-free survival (PFS) relative to … [Read more…]

– After more than five years of follow-up, CABOMETYX in combination with Opdivo continued to show survival benefit compared with sunitinib – – Long-term efficacy seen across subgroups, including site of metastases – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in … [Read more…]

Watch “The Self-Love Letter Project” Campaign Video HERE, Created in Partnership with ATTN: SACRAMENTO, Calif.–(BUSINESS WIRE)–BrightLife Kids, a free mental health and wellness platform for children and families backed by the California Department of Health Care Services (DHCS), today launched The Self-Love Letter Project, a first-of-its-kind initiative encouraging elementary school children to write love letters … [Read more…]

In the MOTION Phase 3 study, ROMVIMZA met primary endpoint of improved objective response rate (ORR) compared to placebo and all key secondary endpoints with statistically significant and clinically meaningful improvements in quality-of-life measures, and demonstrated well-tolerated safety profile OSAKA, Japan & WALTHAM, Mass.–(BUSINESS WIRE)–Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) … [Read more…]

Results presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2025) Treatment with UGN-102 resulted in durable complete response (CR) rates across subgroups with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) CR rates were: 82.8% for patients with a tumor burden ≤3 cm compared to 73.2% for those with a … [Read more…]

PARSIPPANY, N.J.–(BUSINESS WIRE)–$ZTS #HPAI–Zoetis today announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is labelled for use in chickens. The conditional license was granted on the demonstration of safety, purity, and reasonable … [Read more…]

ELMSFORD, N.Y.–(BUSINESS WIRE)–NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced the completion of the acquisition of ENvue Medical Holdings Corp. (“ENvue”) (the “Acquisition”), a privately-held, innovative leader in enteral feeding solutions. This strategic transaction will combine the strengths of both companies, creating a platform for growth … [Read more…]

MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q1 Fiscal 2025 financial results on Friday, February 21, 2025, before markets open. A conference call and webcast to discuss the financial results will be held on Friday, February 21, 2025, at 8:30am ET. … [Read more…]

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ARCADIA clinical trial programs, showing that Nemluvio has the potential to address the significant unmet needs of patients with atopic dermatitis and prurigo nodularis1-3 There is a need for new … [Read more…]

Estimated annual per member per month organ transplant costs rise 5.2% (age 65 or less) and 9.1% (ages 65+) since 2020 SEATTLE–(BUSINESS WIRE)–Milliman, Inc., a premier global actuarial consulting, risk management, and technology firm, today released its 2025 report on U.S. organ and tissue transplant costs and utilization. This comprehensive study provides valuable insight into … [Read more…]